- Home
- STKS vs PRLD Comparison
STKS vs PRLD Comparison
Compare STKS & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STKS
- PRLD
- Stock Information
- Founded
- STKS 2004
- PRLD 2016
- Country
- STKS United States
- PRLD United States
- Employees
- STKS N/A
- PRLD N/A
- Industry
- STKS Restaurants
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- STKS Consumer Discretionary
- PRLD Health Care
- Exchange
- STKS Nasdaq
- PRLD Nasdaq
- Market Cap
- STKS 77.7M
- PRLD 69.1M
- IPO Year
- STKS N/A
- PRLD 2020
- Fundamental
- Price
- STKS $1.90
- PRLD $1.19
- Analyst Decision
- STKS Hold
- PRLD Strong Buy
- Analyst Count
- STKS 3
- PRLD 3
- Target Price
- STKS $4.50
- PRLD $4.00
- AVG Volume (30 Days)
- STKS 68.8K
- PRLD 3.3M
- Earning Date
- STKS 11-06-2025
- PRLD 10-31-2025
- Dividend Yield
- STKS N/A
- PRLD N/A
- EPS Growth
- STKS N/A
- PRLD N/A
- EPS
- STKS N/A
- PRLD N/A
- Revenue
- STKS $834,363,000.00
- PRLD $7,000,000.00
- Revenue This Year
- STKS $26.58
- PRLD N/A
- Revenue Next Year
- STKS $5.37
- PRLD N/A
- P/E Ratio
- STKS N/A
- PRLD N/A
- Revenue Growth
- STKS 96.64
- PRLD N/A
- 52 Week Low
- STKS $1.86
- PRLD $0.61
- 52 Week High
- STKS $5.26
- PRLD $4.22
- Technical
- Relative Strength Index (RSI)
- STKS 25.42
- PRLD 45.87
- Support Level
- STKS $2.49
- PRLD $1.43
- Resistance Level
- STKS $2.44
- PRLD $4.19
- Average True Range (ATR)
- STKS 0.14
- PRLD 0.40
- MACD
- STKS -0.06
- PRLD -0.05
- Stochastic Oscillator
- STKS 6.33
- PRLD 0.00
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.